Company intelligence / Profile preview
Innovate Biopharmaceuticals
Raleigh, North Carolina, United Statesinnovatebiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Larazotide acetate (INN‑202) met its primary endpoint in a phase 2b trial for celiac disease, showing reduction of clinical symptoms and favorable safety profile. It received FDA Fast Track designation and advanced to phase 3 trials. INN‑108 entered phase 2 trials for mild-to-moderate ulcerative colitis, designed as a colon-targeted prodrug with local anti-inflammatory effects. Other pipeline assets included early-stage programs for NASH and Crohn’s.
- Therapeutic areas
- Gastroenterology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Research collaboration with Massachusetts General Hospital on alcoholic steatohepatitis therapy development
Beyond the preview
Go deeper on Innovate Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innovate Biopharmaceuticals.